Sergey Jakimov, LongeVC: Impacting Lives Through Longevity & Health Investing

Sergey Jakimov explains how Longevity VC’s first fund, launched in 2021 with $25 million, has already delivered more than a 3‑times multiple and recorded zero write‑offs. The team screened roughly 2,500 companies, invested in just 20, and secured over $3 billion in pharma commitments from its portfolio. This disciplined, outcome‑focused model leverages deep access to leading academic labs and early‑stage biotech founders, turning patient‑outcome potential into financial upside. PitchBook places the fund in the top quartile of its vintage, underscoring the power of rigorous due‑diligence in the nascent longevity sector.

The fund’s edge lies in its scientific advisory board, a roster of Nobel laureates, AI‑driven drug‑discovery pioneers, and stem‑cell experts from institutions such as Stanford, Harvard and UCLA. Board members vet every deal, ensuring that only disease‑modifying, age‑related therapies progress. By marrying cutting‑edge aging biology with traditional biotech development pathways, Longevity VC targets a trillion‑dollar market spanning autoimmune, endocrine and oncologic indications. The strategy also embraces AI platforms, exemplified by early investments in Encelico Medicine, which now commands a near‑$2 billion valuation. This hybrid approach positions the firm at the intersection of biotech, artificial intelligence, and regenerative medicine.

Building on that success, Fund 2 aims to raise $120 million, deploying larger tickets while preserving the same rigorous sourcing process. The expanded capital will accelerate investments in therapeutic pipelines and AI discovery engines, capitalising on big‑pharma’s current cash surplus and appetite for pre‑clinical acquisitions. Limited partners benefit from co‑investment rights, direct access to the advisory board, and regular immersion events with leading longevity physicians. As pharma seeks to replenish pipelines through M&A, Longevity VC’s deep network and non‑dilutive grant arm, the Longevity Science Foundation, provide a sustainable pipeline of investable breakthroughs. The firm’s roadmap promises outsized returns while advancing health‑span extensions for patients worldwide.